0 194

Cited 1 times in

Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients

Authors
 Hyung Shin Yoon  ;  Kotaro Hattori  ;  Daimei Sasayama  ;  Hiroshi Kunugi 
Citation
 JOURNAL OF AFFECTIVE DISORDERS, Vol.232 : 134-138, 2018 
Journal Title
 JOURNAL OF AFFECTIVE DISORDERS 
ISSN
 0165-0327 
Issue Date
2018
MeSH
Adult ; Antidepressive Agents/therapeutic use ; Biomarkers/cerebrospinal fluid ; Depressive Disorder, Major/cerebrospinal fluid* ; Depressive Disorder, Major/psychology ; Female ; Humans ; Immunoassay ; Male ; Middle Aged ; Nerve Tissue Proteins/cerebrospinal fluid* ; Neurotransmitter Agents/cerebrospinal fluid* ; Psychiatric Status Rating Scales
Keywords
Antidepressant ; Cerebrospinal fluid ; Cocaine- and amphetamine-regulated transcript ; HAMD-21 scale ; Major depressive disorder ; Neuropeptides
Abstract
BACKGROUND: Cocaine- and amphetamine-regulated transcript (CART) peptide is a candidate neuropeptide as a biomarker for major depressive disorder (MDD) because of its effects on emotion and distribution covering brain areas involved in the pathophysiology of MDD symptoms. However, it is unknown whether CART peptide levels are altered in the cerebrospinal fluid (CSF) of patients with MDD patients and are correlated with MDD symptoms. METHODS: Subjects were 24 patients with MDD and 25 healthy controls matched for age, gender and ethnicity (Japanese). We measured CSF CART levels by a commercially available immunoassay kit and analyzed the relationships of the levels with antidepressant dose and symptoms assessed with the 21 item Hamilton Depression Rating Scale (HAMD-21). RESULTS: CSF CART levels were significantly decreased in the patients than in the controls (p < 0.05). In MDD patient group, the CART levels had a negative correlation with antidepressant dose (imipramine-equivalent dose) (ρ = -0.55, p < 0.01) and significantly decreased in antidepressant-treated group (AD-treated group) compared to controls (p < 0.05). CSF CART levels showed significant negative correlations with psychomotor retardation, somatic anxiety, and general somatic symptoms (all p < 0.05) and a positive correlation with obsessive and compulsive symptoms (p < 0.05). LIMITATIONS: In our analysis, all classes of antidepressants were combined together and the effects of medication use in a longitudinal manner did not confirm. CONCLUSIONS: We report for the first time that CSF CART peptide levels are reduced in patients with MDD compared with healthy controls. The CART levels showed negative correlations with antidepressant dose and some symptoms, supporting the possibility that CART peptide is involved in the development of depressive symptoms.
Full Text
https://www.sciencedirect.com/science/article/pii/S0165032717318530
DOI
10.1016/j.jad.2018.02.039
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Physiology (생리학교실) > 1. Journal Papers
Yonsei Authors
Yoon, Hyung Shin(윤형신) ORCID logo https://orcid.org/0000-0003-4389-7578
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/164970
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links